MedTrace Logo

Lacosamide in Neonatal Status Epilepticus

NCT05291455 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-03-22

No results posted yet for this study

Summary

Lacosamide in neonatal status epilepticus

Conditions

Interventions

DRUG

Lacosamide

lacosamide will be given

DRUG

Phenobarbital

phenobarbital will be given

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • abeer salamah, lecturer · Kafrelsheikh University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
28 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2024-03-01
Completion
2024-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05291455 on ClinicalTrials.gov